June 2024

www.sganalytics.com

ZEST

ONE-STOP SOLUTION FOR HEALTHCARE INSIGHTS

NEWSLETTER ISSUE 2

SG Analytics' premium healthcare monthly newsletter,

your gateway to the latest advancements, trends, and strategies in the world of MedTech, Pharma and Digital Health.

Each edition of Zest will bring you an insightful analyses,

expert opinions, and exclusive updates that will keep you at the forefront of the healthcare industry's transformation.

SG Analytics

Life's Possible



Contents

01

CRISPR Therapy: Unlocking the Potential of Gene Editing

Introduction

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is like a tiny pair of molecular scissors that bacteria use to defend themselves against viruses. Scientists figured out how to harness this natural defense system and repurpose it as a gene-editing tool.

Here's how it works: CRISPR has two main parts–a protein called Cas9 (the scissors) and a guide RNA (the GPS). The guide RNA shows Cas9 exactly where to cut in the DNA, allowing scientists to make precise changes to the genetic code. CRISPR can delete, insert, or modify specific DNA sequences.

This technology opens a world of possibilities. Scientists can use it to study genetic diseases, develop new treatments, and even engineer crops more resistant to pests or environmental stress. However, there are ethical concerns about how CRISPR could be used—like editing human embryos to prevent genetic diseases or creating "designer babies" with desired traits. So, while CRISPR holds an incredible promise, it's important to proceed cautiously and consider the implications of tinkering with the building blocks of life.

~ 100,000

people in the US are affected by sickle cell disease.

1st in the world,

on November 16, 2023, the CRISPR-based gene therapy Casgevy was approved in the UK for sickle cell disease and transfusion-dependent beta-thalassemia.

Figure 1: CRISPR Therapy



Table 1: Difference between Prime Editing and Base Editing

Aspect	Prime Editing	Base Editing
Mechanism	Introduces precise changes without causing double-strand breaks (DSBs) in DNA.	Modifies individual DNA bases without DSBs, using a deaminase enzyme.
Editing Precision	Can create precise insertions, deletions, and all 12 types of point mutations.	Allows targeted changes to individual DNA bases (single-nucleotide changes).
Components	- Cas9 nickase (nCas9)	- Cas9 nickase (nCas9)
	- Reverse Transcriptase (RT)	- Nucleoside Deaminase
	- Prime-Editing Guide RNA (pegRNA)	
Efficiency	Scientists are working to enhance efficiency by developing PE variants with improved features.	Second-generation base editors include uracil glycosylase inhibitors (UGIs) to enhance efficiency.
pegRNA Design	Relies on pegRNA for target sequence and desired genetic modification.	Base editing relies on the base-editor complex.

Aspect	Prime Editing	Base Editing
INDEL Generation	Rare occurrence of INDELs due to nicking in the non-edited DNA strand.	INDELs can occur during repair processes.
Mismatch Repair (MMR)	MMR machinery repairs mismatches in the noncomplementary strand.	Researchers introduce silent mutations to increase mismatches between edited and non-edited strands.
Edit Size	Can introduce larger edits (up to 10 kilobases) by combining pegRNAs or using recombination.	Limited to relatively short insertions and deletions.
Applications	Precision medicine, agriculture, biotechnology, and research.	Ideal for single-nucleotide changes associated with genetic diseases.
Off-target Effects	Lower off-target editing than Cas9 nuclease.	Can affect RNA independently of Cas9 activity.

Exploring the Pros and Cons of CRISPR Gene Editing

Advantages of CRISPR:

- **Potential to Prevent Birth Defects:** CRISPR holds the potential to correct genetic defects before birth, offering the possibility of preventing inherited diseases from being passed down to future generations.
- **Proven Success:** Documented successes in treating diseases including hemophilia, leukemia, and certain types of blindness highlight the efficacy of CRISPR in addressing genetic disorders.
- **High Potential for Treating Various Conditions:** The precise nature of CRISPR's gene editing capabilities opens doors for treating a wide range of conditions, offering hope to patients with diverse medical needs.
- **Specific Autologous Treatments:** CRISPR enables personalized treatments by modifying a patient's own cells, paving the way for tailored therapies that minimize the risk of rejection.
- **Permanent Results:** A few CRISPR treatments may offer a one-time and permanent cure, eliminating the need for ongoing treatment regimens.
- **Rapid Development:** The rapid pace of advancement in the field of CRISPR holds promise for the development of novel applications and treatment strategies.
- **Combination with Cell Therapy:** CRISPR can complement cell therapy approaches, enhancing the efficacy of treatment strategies for certain conditions.
- **Targeted Cancer Treatment:** CRISPR's precision allows for the targeted delivery of anticancer agents to tumor cells, minimizing damage to surrounding healthy tissues.
- **No Long-term Expression Needed:** Unlike traditional gene therapy methods, CRISPR does not require long-term expression of a transgene, reducing the risk of unintended consequences.

Disadvantages of CRISPR:

- **Undesired Immune Reactions:** The body may mount immune responses to CRISPR components, posing a risk of adverse reactions in several individuals.
- **Mistargeting:** Incorrect gene editing could lead to unpredictable genetic alterations, potentially causing unintended consequences for patients.
- **Pathogenicity of Delivery Viruses:** Viruses used to deliver CRISPR components may regain their ability to cause disease, posing risks to patient safety.
- **Potential Tumors:** There's a risk that CRISPR editing could inadvertently activate oncogenes, leading to the development of cancerous tumors.
- **Gene Therapy Not Guaranteed:** While CRISPR shows promise, it does not guarantee success in all cases, highlighting the need for further research and development.
- **Incompatibility:** The genetic makeup of several individuals may not be suitable for CRISPR treatments, limiting its efficacy in certain populations.
- **Resistance Development:** Over time, there's a possibility that humans might develop resistance to CRISPR treatments, reducing their effectiveness.
- **Cost Prohibitive:** The high cost of CRISPR treatments may make them unaffordable for many patients, limiting access to potentially life-saving therapies.
- **Ethical Concerns:** CRISPR raises ethical questions, particularly regarding germline modifications and the potential for unintended consequences.
- **Reduced Efficacy:** CRISPR may be less efficient in treating diseases caused by multiple-gene mutations, posing challenges for certain conditions.



Recent Innovations and Trends in CRISPR Therapy:
See Figure 2 at end of the document.

Disadvantages of CRISPR:

1

Gene Therapy

- **Casgevy:** FDA-approved CRISPR treatment for sickle cell disease.
- **Mechanism:** Modifies genes to correct red blood cell shape and function.
- **Impact:** Demonstrates a functional cure for a minimum of one year.

2

Cancer Treatment

- **CD70-targeting CAR-T cells:** Showed a 77% disease control rate in trials.
- **Advancement:** CRISPR therapeutics working on an updated version targeting additional genomic sites.

3

HIV/AIDS Cure Research

- **EBT-101:** Excision Bio's in vivo gene therapy received FDA fast-track status.
- **Goal:** Remove integrated retrovirus from human cell genomes.

4

Inherited Diseases Prevention

- **CFTR Gene Editing:** Potential to prevent or ameliorate cystic fibrosis.
- **Current Status:** Vertex developed CFTR modulators, not yet utilizing CRISPR.

5

Antibiotic-resistant Bacteria Control

- **Strategy:** Target and eradicate harmful bacterial strains using CRISPR-Cas.
- **Potential:** Manage bacterial drug resistance and horizontal gene transfer.

6

Rare Diseases Treatment

- **Duchenne Muscular Dystrophy (DMD):** Researching CRISPR correction of dystrophin gene mutations.
- **Hope:** Restore muscle function and improve quality of life.

7

Organ Transplantation

- **Xenotransplantation:** Modify donor animal genes to reduce immune rejection risks.
- **Milestone:** University of Maryland's historic pig heart transplant using CRISPR.

8

Neurodegenerative Diseases Research

- **Model Creation:** Study diseases such as Alzheimer's and Parkinson's.
- **Progress:** Deleting the A53T-SNCA gene improved Parkinson's disease conditions.

9

Malaria Prevention

- **Target:** Plasmodium parasites and mosquito vectors.
- **Achievement:** Generated malaria-resistant mosquitoes and identified antimalarial compounds.

10

Enhanced Drug Discovery

- **CRISPR Screens:** Identify and validate potential drug targets.
- **Capability:** High sensitivity and single-base specificity.

Key Milestones

"Casgevy: CRISPR Therapy Breakthrough - Approved but Accessible?"

- **Approved Status:** Casgevy secures regulatory approval in the UK, the US, EU, and Bahrain for its CRISPR-based therapy targeting Sickle Cell Disease (SCD) and Transfusion-Dependent Thalassemia (TDT).
- **Clinical Success:** Phase 3 trial results demonstrate significant and sustained increases in fetal hemoglobin, leading to reduced disease symptoms.
- **Accessibility Challenges:** The high cost of $2 million per patient poses barriers to access, compounded by the need for specialized treatment facilities.
- **Insurance and Medicaid Coverage:** Pending decisions in the US raise concerns about affordability and equitable access to treatment.
- **Safety Concerns:** Pre-treatment chemotherapy regimen presents risks, prompting ongoing research to enhance safety protocols and reduce costs.
- **Future Prospects:** Despite challenges, Casgevy's approval marks a pivotal moment in precision medicine, offering hope to millions of people affected by genetic disorders.

93.5%

efficacy rate was achieved by Casgevy in the clinical trial.

Pipeline Analysis

Table 2: CRISPR Therapy Pipeline Product Portfolio

Conditions	Interventions	Sponsor	Phases	Completion Date
Diabetes Mellitus	COMBINATION_PRODUCT: VCTX211	CRISPR Therapeutics	Phase I/II	2025-08
Beta-Thalassemia	BIOLOGICAL: CTX001	Vertex Pharmaceuticals	Phase III	2025-02
HIV-1-infection	BIOLOGICAL: EBT-101	Excision BioTherapeutics	Phase I	2025-05
Gastrointestinal Epithelial Cancer	BIOLOGICAL: Tumor-Infiltrating Lymphocytes (TIL)	Intima Bioscience.	Phase I/II	2024-01
Renal Cell Carcinoma	BIOLOGICAL: CTX131	CRISPR Therapeutics	Phase I/II	2030-05
Beta-Thalassemia	BIOLOGICAL: CTX001	Vertex Pharmaceuticals	Phase III	2026-05
Eye Disorder	DRUG: EDIT-101	Editas Medicine	Phase I/II	2025-05
T Cell Lymphoma	BIOLOGICAL: CTX130	CRISPR Therapeutics	Phase I	2027-05
B-cell Lymphoma	BIOLOGICAL: CTX110	CRISPR Therapeutics	Phase I/II	2026-08
B-cell Lymphoma	BIOLOGICAL: CTX112	CRISPR Therapeutics	Phase I/II	2030-02
Hereditary Angioedema	BIOLOGICAL: Biological NTLA-2002	Intellia Therapeutics	Phase I/II	2025-12
Diabetes Mellitus (Type 1)	COMBINATION_PRODUCT: VCTX210A unit	CRISPR Therapeutics	Phase I	2023-01
Beta-Thalassemia	BIOLOGICAL: ET-01	EdiGene (GuangZhou)	Phase I	2024-06
Sickle Cell Disease	BIOLOGICAL: CTX001	Vertex Pharmaceuticals Incorporated	Phase II/III	2024-10
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	BIOLOGICAL: NTLA-2001	Intellia Therapeutics	Phase I	2026-08

Conditions	Interventions	Sponsor	Phases	Completion Date
Sickle Cell Disease	GENETIC: nula-cel Drug Product	Kamau Therapeutics	Phase I/II	2027-07
Multiple Myeloma	BIOLOGICAL: CTX120	CRISPR Therapeutics AG	Phase I	2027-01
Beta-Thalassemia	BIOLOGICAL: CTX001	Vertex Pharmaceuticals Incorporated	Phase II/III	2024-08
Renal Cell Carcinoma	BIOLOGICAL: CTX130	CRISPR Therapeutics AG	Phase I	2027-04
Retinitis Pigmentosa	DRUG: ZVS203e	Peking University Third Hospital	Early phase I	2026-04
Sickle Cell Disease	BIOLOGICAL: CTX001	Vertex Pharmaceuticals Incorporated	Phase III	2026-05

Challenges for CRISPR Therapy

Immunogenicity

CRISPR components such as Cas9 and delivery vectors can trigger immune responses, leading to adverse reactions and potential failure in genome editing. Strategies to mitigate this include:

- **Modifying guide RNAs**
- **Developing novel Cas proteins**
- **Monitoring immune reactions during clinical trials**

Off-targeting

CRISPR/Cas9 can inadvertently bind to non-target genomic regions, causing unwanted mutations. Techniques to reduce off-target effects include:

- **Using high-fidelity SpCas9**
- **Employing bioinformatics tools**
- **Utilizing non-integrative vectors like adenovirus**

Mutations

Cancer treatment with CRISPR is complex due to multiple gene mutations. Correcting tumor suppressor genes and blocking oncogenes is challenging and requires:

- **Multiple guide RNAs**
- **Combining Cas9 and Cas12a proteins**
- **Using bioinformatic tools**

Delivery Techniques

Effective delivery of CRISPR to target cells remains difficult. Viral vectors are commonly used but pose risks. Emerging methods including lipid nanoparticles and nanoclusters offer potential solutions but face challenges such as:

- **Production difficulties**
- **Toxicity concerns**

Ethics

The far-reaching implications of CRISPR-mediated genome editing necessitate careful ethical and societal consideration to ensure the responsible use of this powerful technology.

Future Outlook for CRISPR Technology

Advancements and Applications

- **Refinement of CRISPR Tools:** Continued advancements in CRISPR-Cas systems and editing techniques are expected, enhancing precision, efficiency, and safety.
- **Expanded Applications:** CRISPR technology will find broader applications beyond gene editing, including diagnostics, epigenetic modifications, and therapies for complex diseases.
- **Preclinical Success:** Numerous preclinical studies have demonstrated CRISPR's potential in correcting genetic defects and treating a range of diseases.
- **Clinical Trials:** The approval of more clinical trials marks a significant step toward the application of CRISPR in therapeutic settings, bringing hope for curing genetic conditions.
- **Societal Impact:** Ethical considerations will continue to shape the use of CRISPR, influencing regulatory decisions and public discourse.

Impact on Key Sectors

- **Healthcare:** CRISPR-based therapies hold promise for personalized medicine, offering targeted treatments for genetic diseases and potentially revolutionizing cancer therapies and infectious disease treatments.
- **Biotechnology:** CRISPR technology's applications in bioproduction and bioengineering may lead to the creation of novel biomaterials, pharmaceuticals, and industrial chemicals, fostering innovation in various industries.

Figure 2 Recent Innovations and Trends in CRISPR Therapy

1

Gene Therapy

- **CASGEVY:** FDA-approved CRISPR treatment for sickle cell disease.
- **Mechanism:** Modifies genes to correct red blood cell shape and function.
- **Impact:** Demonstrates a functional cure for a minimum of one year.

2

Cancer Treatment

- **CD70-targeting CAR-T cells:** Showed a 77% disease control rate in trials.
- **Advancement:** CRISPR Therapeutics working on an updated version targeting additional genomic sites.

3

HIV/AIDS Cure Research

- **EBT-101:** Excision Bio's in vivo gene therapy received FDA fast-track status.
- **Goal:** Remove integrated retrovirus from human cell genomes.

4

Antibiotic-Resistant Bacteria Control

- **Strategy:** Target and eradicate harmful bacterial strains using CRISPR-Cas.
- **Potential:** Manage bacterial drug resistance and horizontal gene transfer

5

Rare Diseases Treatment

- **Duchenne Muscular Dystrophy (DMD):** Researching CRISPR correction of dystrophin gene mutations.
- **Hope:** Restore muscle function and improve quality of life

6

Organ Transplantation

- **Xenotransplantation:** Modify donor animal genes to reduce immune rejection risks.
- **Milestone:** University of Maryland's historic pig heart transplant using CRISPR

7

Neurodegenerative Diseases Research

- **Model Creation:** Study diseases like Alzheimer's and Parkinson's.
- **Progress:** Deleting A53T-SNCA gene improved Parkinson's disease conditions

8

Malaria Prevention

- **Target:** Plasmodium parasites and mosquito vectors.
- **Achievement:** Generated malaria-resistant mosquitoes and identified antimalarial compounds

Conclusion

CRISPR technology represents a monumental leap forward in genetic engineering, offering unprecedented opportunities to understand and treat several genetic disorders. From the ground-breaking approval of Casgevy for sickle cell disease to ongoing research into cancer, HIV, and other conditions, CRISPR's impact on medicine and biotechnology is profound. However, this powerful tool comes with significant ethical and practical challenges, including high costs, potential off-target effects, and societal implications. As we continue to refine CRISPR techniques and expand their applications, it is crucial to balance innovation with responsibility, ensuring that the benefits of gene editing are accessible, safe, and ethically sound. The future of CRISPR holds immense promise and its continued development will likely transform the landscape of modern medicine and beyond.

Manoj Mote

Intern - Life Sciences & Healthcare

LinkedIn

02

Transforming Neurological Care: The Impact of Digital Health Technologies

The field of digital health in neurological disorders is rapidly evolving, encompassing numerous technologies and solutions aimed at enhancing neurological care. This domain encompasses a wide array of digital tools and platforms, including telemedicine, mobile health applications, wearable devices, and AI-driven diagnostics and treatment systems tailored specifically for neurological conditions. The integration of digital health technologies is profoundly impacting the diagnosis, management, and treatment of neurological disorders, ushering in improvements in accuracy, accessibility, and patient outcomes across a spectrum of conditions such as epilepsy, Parkinson's disease, multiple sclerosis, and Alzheimer's disease.

Below mentioned are a few factors that drive the digital health sector, particularly in neurology:

- Technological Advancements
- Rising Prevalence of Neurological Disorders
- Aging Population
- Remote Patient Monitoring
- Telemedicine and Virtual Consultations

98%

of neurologists used telehealth, according to the American Medical Association's telehealth survey.

Here's an overview of how digital health is transforming the landscape for neurological disorders:

Wearable Devices and Remote Monitoring

Wearable devices equipped with sensors are revolutionizing the way neurological disorders are monitored. These devices provide continuous, real-time data, empowering both patients and healthcare providers to make informed decisions about treatment and management strategies.

Epilepsy

Embrace2 for Epilepsy

Seizure Detection

Devices such as the Empatica Embrace2 and the SmartWatch Inspyre by SmartMonitor monitor physiological signals, such as heart rate and electrodermal activity, to detect and alert patients and caregivers about seizures in real-time. Newer wearables such as Empatica Embrace 3 and Epoc by Emotiv go beyond seizure detection to monitor sleep patterns and emotional states in epilepsy patients.

Zeto ONE for EEG Brain Monitoring

EEG Monitoring

Portable and wearable EEG devices such as the Epilog and Zeto provide continuous monitoring and can be used in home settings, improving the detection and diagnosis of epilepsy. In June 2024, the FDA cleared Zeto's ONE headset, a new generation device with 21 soft-tip electrodes for convenient and user-friendly EEG monitoring.

Parkinson's Disease

Kinesia Sensor to Measure Three-dimensional Movement

Symptom Tracking

Devices such as the Kinesia system by Great Lakes NeuroTechnologies and the Personal KinetiGraph (PKG) by Global Kinetics track motor symptoms such as tremors, bradykinesia, and dyskinesia, provide detailed reports to healthcare providers for better management.

Smartwatches

Apps integrated with smartwatches, such as the Apple Watch, use sensors to monitor movement patterns and provide data on tremor intensity and frequency. Smartwatches with fall detection algorithms are being explored for preventing head injuries in patients with Parkinson's disease.

Artificial Intelligence and Machine Learning

Artificial Intelligence (AI) is reshaping the landscape of neurological diagnostics by analyzing complex data patterns and identifying subtle abnormalities that may indicate the presence of a neurological disorder. Machine Learning (ML) algorithms are being trained on vast datasets of neuroimaging studies, genetic profiles, and clinical data to develop more accurate diagnostic tools, leading to earlier detection and intervention.

Diagnosis and Prognosis



Aidoc Full Brain AI Posterior, Anterior, and Distal

MRI and CT Scan Analysis

AI algorithms developed by companies including Aidoc and Qure.ai enhance the interpretation of brain scans, helping to identify anomalies associated with neurological conditions such as tumors, stroke, and traumatic brain injury.



Cognoa Canvas Dx to Diagnose or Rule Out Autism

Early Detection of Alzheimer's

AI tools from companies such as Cognoa and Neurotrack analyze cognitive tests and behavioral data to detect early signs of Alzheimer's and other dementias.

Predictive Analytics

Disease Progression

AI platforms use patient data to predict disease progression in conditions such as multiple sclerosis and Parkinson's disease, enabling personalized treatment plans.

Telemedicine and Remote Consultations

Telemedicine has emerged as a vital tool for patients with neurological disorders, particularly those living in remote areas or facing mobility challenges. Through video consultations and remote monitoring platforms, neurologists can conduct assessments, adjust medications, and provide ongoing support to patients, enhancing access to care and improving outcomes.

Access to Neurologists

Teladoc - Telehealth & Telemedicine Provider

TeleSpecialists - Telemedicine for TeleNeurology & TeleStroke

Virtual Consultations

Platforms such as Teladoc and Amwell facilitate remote consultations with neurologists, providing patients in remote or underserved areas with access to specialized care.

TeleNeurology

Dedicated telemedicine services for neurology, such as TeleSpecialists, provide telemedicine solutions for quality-focused hospitals and healthcare systems.

Digital Biomarkers and Health Analytics

Digital biomarkers are quantifiable, objective, and physiological data collected and measured by digital devices. In neurological disorders, these biomarkers offer a novel approach to monitor disease progression, predict outcomes, and tailor treatments. Health analytics, which involves the use of computational techniques to analyze health data, plays a crucial role in extracting meaningful insights from digital biomarkers.

Cognitive Assessments



Lumosity App

Digital Cognitive Tests

Tools such as the Cambridge Cognition's CANTAB and the Lumosity app provide digital cognitive assessments that help in diagnosing and monitoring conditions such as mild cognitive impairment (MCI) and Alzheimer's disease.

Mobile Health Apps

SeizAlarm - Irregular Movement Detection Mobile App

Symptom Tracking and Management

- Apps such as Parkinson's Mind Movement use gamified elements and voice coaching to help patients with Parkinson's practice exercises and improve motor skills.
- SeizAlarm integrates with Apple Watch to detect potential seizure activity through heart rate and movement data, alerting caregivers and providing emergency assistance.

Virtual Reality and Augmented Reality

Virtual Reality (VR) and Augmented Reality (AR) have increasingly been explored for their potential applications in the diagnosis, treatment, and rehabilitation of neurological disorders.

Rehabilitation and Therapy

Parkinson's VR by PhysioVR

VR for Stroke Rehabilitation

VR platforms including Parkinson's VR by PhysioVR uses immersive environments that challenge balance and gait. Patients navigate virtual landscapes with obstacles and uneven terrain, practicing walking exercises in a safe and engaging way.

AR for Cognitive Training

AR tools provide interactive cognitive training exercises for patients with neurodegenerative disorders, enhancing engagement and effectiveness.

Pain Management

RelieVRx by AppliedVR In-home VR Treatment

VR for Chronic Pain

VR applications such as those developed by AppliedVR provide immersive environments that help in managing chronic pain associated with neurological disorders through distraction and relaxation techniques.

Genomic and Personalized Medicine

Genetic Testing

Invitae Hereditary Parkinson Disease and Parkinsonism Panel

Identification of Genetic Mutations

Companies such as Invitae and 23andMe offer genetic testing that can identify mutations associated with neurological disorders, aiding in early diagnosis and personalized treatment planning.

CRISPR and Gene Therapy



23andMe DNA Ancestry Test Kit

Research and Treatment

Advances in CRISPR technology are being explored for the treatment of genetic neurological disorders such as Huntington's disease and spinal muscular atrophy (SMA).

Electronic Health Records and Data Integration

Electronic Health Records (EHRs) and data integration play a crucial role in the management and treatment of neurological disorders. They offer numerous benefits, including improved patient care, streamlined workflows, and enhanced research opportunities.

Interoperability

Neurology Cloud-based EHR and Practice Management

Integrated Care

- Enhanced EHR systems ensure that neurological data, including imaging, genetic, and digital health data, are integrated and accessible to healthcare providers, improving coordination and continuity of care.
- **WRS Health (Neurology Cloud)**, a cloud-based EHR platform offers neurology-specific templates, real-time medication management, and secure messaging functionalities.

Clinical Decision Support

AI-driven Insights

- AI-integrated EHR systems provide clinical decision support by analyzing patient data and offering insights into potential diagnoses and treatment options.
- These advancements in digital health are significantly enhancing the diagnosis, management, and treatment of neurological disorders, leading to better patient outcomes and improved quality of life. As technology continues to evolve, the integration of AI, wearables, telemedicine, and other digital tools will further revolutionize neurological care.

Challenges and Barriers in Digital Health for Neurological Disorders

Even though digital health offers a wide range of benefits for neurological care, there are still challenges and barriers that need to be addressed:

- **Data Privacy and Security:** Concerns exist around protecting sensitive patient data collected by wearables, mobile apps, and other digital tools. Breaches and misuse of this data can have serious consequences.
- **Accessibility and Equity:** Not everyone has equal access to smartphones, tablets, and internet connectivity required for many digital health solutions. This can exacerbate existing disparities in healthcare access.
- **Cost and Reimbursement:** The development, implementation, and maintenance of digital health technologies can be expensive. Reimbursement policies may not adequately cover these costs, limiting their widespread adoption.
- **Integration with Traditional Healthcare:** Seamless integration of digital health tools with EHRs and existing healthcare workflows is crucial for optimal patient care. This can be challenging due to technical and logistical hurdles.
- **Validation and Standardization:** The effectiveness and reliability of digital health interventions need to be rigorously evaluated and standardized to ensure quality and patient safety.
- **Limited Digital Literacy:** A few patients, particularly older adults, may lack the digital literacy skills required to use certain digital health tools effectively.
- **Algorithmic Bias:** AI algorithms used for diagnostics and treatment decisions can perpetuate biases present in the data they are trained on. This can lead to inaccurate diagnoses and unfair treatment recommendations.

These challenges need to be addressed to ensure that digital health technologies reach their full potential in transforming neurological care.

Future Outlook

The future of digital health in neurology holds tremendous promise, with ongoing advancements expected to further transform the landscape. Emerging technologies such as advanced AI algorithms, more sophisticated wearable devices, and innovative applications of VR and AR in therapy and rehabilitation will continue to enhance patient outcomes. The expansion of genomic and personalized medicine, including genetic testing and gene therapy, is poised to provide tailored treatment options for genetic neurological disorders. Integration of EHRs with AI-driven clinical decision support will improve data accessibility and streamline care coordination. As these technologies evolve, they will likely lead to more proactive and preventive approaches in neurological care, ultimately improving the quality of life for patients worldwide. Continued investment in research and development, along with collaboration between technology developers, healthcare providers, and policymakers, will be crucial in realizing the full potential of digital health in neurology.

Sonali Phale

Lead Analyst - Life Sciences & Healthcare

LinkedIn

03

Anti-obesity Drugs Landscape and Its Impact on Medical Devices Industry

Overview of Anti-obesity Drug:

With the approval of Tirzepatide (Zepbound) in late 2023, there has been a notable surge in interest and development within the anti-obesity drug market. Analysts project that this market could exceed US$ 100 billion by 2030. These medications, particularly innovative classes such as Tirzepatide, which is a dual receptor agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), exhibit significant potential for weight loss. Tirzepatide activates receptors of these intestinal hormones, thereby reducing appetite and food intake. This remarkable efficacy, however, prompts a critical inquiry: how will the emergence and proliferation of anti-obesity drugs influence the medical device market landscape? Furthermore, it raises the question of why there is a heightened focus on these drugs now, despite the existence of anti-obesity medications for over a century.

1 in 8 people

in the world were living with obesity in 2022, including 890 million adults (18 years and older) and 160 million children and adolescents (5–19 years).

US$3 trillion / year

is the predicted global cost of overweight and obesity by 2030, expected to exceed US$18 trillion by 2060.

Table 3: Key Anti-obesity Drugs Approved in the Market

Medication	Company	FDA Approval Year	Average Weight Loss
Semaglutide (Wegovy)	Novo Nordisk	2021	15%
Tirzepatide (Zepbound)	Eli Lilly	2023	15-20.9% (depending on dose)
Liraglutide (Saxenda)	Novo Nordisk	2014	5-10%
Qsymia (phentermine and topiramate)	Vivus, Inc.	2012 (for adults) 2022 (pediatric patients aged 12 years and older)	5–10%
Setmelanotide (Imcivree)	Rhythm Pharmaceuticals	2020, 2022 (Obesity due to one of several specific rare genetic disorders.)	NA

Anti-obesity drugs are not something new with several molecules having been approved over the past few decades. Historically, these medications have been associated with a weight reduction of approximately 5-10%. However, recent advancements have led to the development of drugs that can achieve a more substantial weight loss, with some reporting an average reduction of around 25%. Eli Lilly's Retatrutide, one of the most promising anti-obesity drugs currently in Phase III trials, demonstrated a 22.4% reduction in body weight over a 48-week period. Retatrutide has shown significant efficacy in reducing liver fat. It is also being investigated for its potential benefits in other conditions, including obstructive sleep apnea, knee osteoarthritis, and chronic kidney disease (CKD).

Wegovy, initially approved as an anti-obesity drug, also received additional approval in March 2024 to prevent life-threatening cardiovascular events in adults with cardiovascular disease who are either obese or overweight. Retatrutide is also being investigated for its potential benefits in other conditions, including obstructive sleep apnea, knee osteoarthritis, and chronic kidney disease (CKD). These expanded indications could enhance the adoption of such drugs among the obese and overweight population, providing broader therapeutic benefits.

Emerging indications and their improved efficacy and non-invasive nature position anti-obesity drugs as preferred treatments. However, their short-term impact is tempered by challenges related to access and reimbursement, along with high out-of-pocket costs as they could cost ~US$ 1,000 per month. Additionally, these therapies may cause gastrointestinal side effects, potentially impeding their near-term adoption.

In the US, reimbursement for anti-obesity drugs is contingent upon patients meeting specific BMI criteria. In March 2024, Medicare expanded coverage to include these drugs, provided evidence supports their effectiveness in reducing conditions such as heart attacks and strokes. This policy change is expected to reduce long-term Medicare spending, highlighting its potential to mitigate healthcare costs over time.

$100 billion

is the projected size of the obesity drugs market by 2030.

~ 580,000

people worldwide undergo bariatric surgery annually, with approximately 40% in the US alone.

Impact on MedTech Industry:

While the current impact on the medical device industry is not significant, any destructive impact is anticipated to occur gradually. Nevertheless, investor concerns are mounting. Companies such as ResMed, Inspire Medical Systems, Zimmer Biomet, and Smith+Nephew have seen declines in their valuations following the introduction of various anti-obesity drugs into the market. The potential areas of impact on the medical device industry include:

Bariatric Surgery:

MedTech firms specializing in devices for bariatric surgery should anticipate that physicians will prioritize non-surgical interventions, potentially influencing market dynamics. However, there is a prospective benefit as GLP-1s may help more patients achieve BMI reductions necessary for bariatric device eligibility.

> "There is likely to be little impact as patients do not typically remain on the drugs for more than a year, adding that the weight loss medications may lead to new patients considering surgery. We believe the current headwinds on US bariatric procedures will stabilize over the next several quarters and return to growth by calendar year 2025, and this is modest and manageable within our broader diversified surgical business."

Geoff Martha

CEO, Medtronic

Orthopedics: Similarly, weight reduction may alleviate joint stress and potentially expand the pool of candidates for knee and hip replacements. Individuals without obesity will likely maintain consistent demand for joint replacements.

Zimmer Biomet Assessing Impact of Potential Impact of GPL-1 Anti-obesity Drugs –

Addressing obesity before surgery can mitigate the risk of complications during orthopedic procedures. Currently, a significant portion of patients are ineligible for joint surgeries due to elevated BMI levels. By addressing obesity beforehand, the potential pool of patients eligible for large joint procedures could expand. It's important to note that obesity is a contributing factor to osteoarthritis, a condition that persists even if weight loss occurs later. Despite ongoing efforts with obesity drugs and surgeries, the obesity rate continues to rise unabated. Concurrently, the demand for joint replacement surgeries shows a consistent annual increase of approximately 5%.

Cardiovascular Devices:

Increasing evidence suggests GLP-1s can lower the incidence of heart attacks and strokes. For instance, findings from the SELECT trial demonstrated a 20% reduction in cardiovascular events with semaglutide among overweight or obese adults with established heart disease and without diabetes. The implications for cardiology practice remain uncertain and likely to be minimal for surgical devices in near term.

Sleep Apnea Devices:

Given that obesity is a leading risk factor for obstructive sleep apnea, weight loss could significantly decrease its prevalence and consequently reduce the demand for CPAP devices. Ongoing clinical trials are examining this relationship, though the market's future will depend on patient treatment trajectories and payer reimbursement policies.

Conclusion

The emergence of novel anti-obesity drugs, such as Tirzepatide, represents a notable advancement with profound implications for healthcare sectors, heralding transformative shifts in treatment approaches and patient health outcomes. Despite existing challenges such as reimbursement complexities and potential adverse effects, the expanding scope of therapeutic applications and supportive regulatory changes point toward a promising trajectory. Companies within the medical device industry should pivot to strategically integrate these pharmacological innovations into holistic healthcare strategies, leveraging synergies with their existing device solutions. This approach should prioritize the enhancement of patient outcomes and adept navigation of evolving market landscapes, thereby securing enduring competitive advantages in the foreseeable future.

Megha Patil

Project Manager - Life Sciences & Healthcare

LinkedIn

04

Navigating Vietnam Pharmaceutical Market: An Irresistible Opportunity for Global Players

Vietnam's pharmaceutical industry is registering significant growth (14.9% CAGR from 2015 to 2020). Most domestic suppliers lack sufficient resources such as R&D infrastructure, manufacturing capacity, and capital to fully exploit the market. Consequently, originator products comprise less than 4% of total market share. In contrast, non-prescription products make up about 70% of the market, with branded and unbranded generics comprising the remaining 26%. This places Vietnam below its ASEAN counterparts, such as Thailand (with 8% originators) and Singapore (14%), in terms of access to innovative medicines.

This article explores the opportunities and challenges faced by global players to leverage their capabilities and establish themselves in the high margin innovative and branded drugs market.

53%

Vietnam's demand for branded medicines can only be met by domestic production capacity.

~ 70%

of the market consists of non-prescription products, with branded and unbranded generics making up the remaining 26%.

Opportunities

Large Market Size

Vietnam boasts a substantial market size, owing to its population exceeding 98 million with average life expectancy of ~76 years. Approximately 30% (30 million) of the population has the financial means to access expensive Western medicine.

Rising Health Insurance, Urbanization, and Diseased Population

The percentage of the population having health insurance skyrocketed to 90% in 2020, up from 60% a decade ago. Vietnam's urbanization rate was at 37% in 2020 and the urban population stood at approximately 36.6 million. Non-communicable diseases were responsible for 81% of disease-related deaths in Vietnam in 2019, as reported by the WHO. The primary causes of death in the country in 2019 included stroke, ischemic heart disease, diabetes, chronic obstructive pulmonary disease, and lung cancer. Vietnam ranks among the top ten countries with the highest burden of tuberculosis.

Low-cost Manufacturing and Lack of Local Competition

Unlike Chinese and Indian markets, local competition for innovative and complex drugs is not a threat, as most domestic manufacturers are small with limited capital, low R&D resources, and GMP non-compliant with underdeveloped supply chains. Our research shows that before purchase by end user, there are at least three distribution layers with multiple players, resulting in high price and low quality. The top three largest wholesalers accounting for ~40% of wholesaling and distribution market share are foreign owned such as Zuellig Pharma (Swiss), Diethelm (Singapore), and Mega Products (Thai).

Underdeveloped Industry

According to the General Statistics Office (GSO), Vietnam's domestic production capacity can only meet 53% of demand. Moreover, the country's capabilities are limited to simple generic medicines and dosage forms. In 2018, Vietnam spent US$ 2.8 billion on importing pharmaceuticals and in 2021, that number jumped to US$ 4 billion. This represents a large opportunity for global players with expertise in R&D.

Free Trade Agreement & Investment Protection Agreement (EVFTA)

Owing to the EVFTA agreements between Vietnam and the European Union (EU) in 2020, Vietnam will eliminate tariffs on pharmaceutical products manufactured in the EU. This is a major boost for EU pharmaceutical companies, which can enter Vietnam at a lower price than before, resulting in level playing field.

Challenges

Over the Counter Nature of the Market

According to EU-Vietnam Business Network (EVBN), 80% of Vietnamese purchase drugs from private pharmacies and self-medicate. Consumers value brands known to them and purchase drugs without a prescription based on advice from relatives/friends.

Misbranded and Counterfeit Drugs

Long Approval Time and Bias Against Global Firms

It takes nearly five years for a drug to enter the Vietnamese market after development. This duration includes around two & a half years dedicated to clinical trials and an additional two & a half years for government approval. However, latest trends indicate that the approval process is extending further due to a significant backlog at the Vietnam National Office of Intellectual Property (NOIP).

FDI logistic companies and foreign pharmaceutical companies are not permitted to distribute pharmaceutical products directly and are required to sell their products to domestic pharmaceutical distributors.

Regional Differences

Global companies entering the market need to consider two marketing efforts; one for targeting the northern part of the country (which has a higher concentration of government offices and regulatory agencies) and one for the south (which is the dominant industry hub). Vietnam also has a spatial difference in incidence rates of many diseases due to geography, which need to be considered. There is a large variation in poverty and urbanization in Vietnam as can be seen from the following figure.

Figure 3: Poverty in Vietnam (by district in % of the population for each district)



The two markets also differ in terms of consumer behavior and preferences. Southern Vietnam contributes nearly 50% of Vietnam's GDP despite having a third of Vietnam's population. The income gap between urban and rural households is also wider in the North. The North is conservative with word of mouth being the most credible source of information, whereas the urban areas and South enjoy higher internet connectivity resulting in greater opportunities for online communication. The incidence of diseases also shows large variations owing to the difference in elevation and climate patterns.

The Right Strategy

With the combination of right strategy, investments, and expertise, global pharmaceutical companies can garner a significant share of the lucrative innovative drugs market. Most developing countries have leveraged the self-funded growth model. The self-funded model emphasizes technology transfer and government support to local industry in the form of financial and legal incentives. China and India serve as glaring examples of this strategy.

However, the self-funded model suffers from inefficiencies and slow growth rate. An alternative is the FDI growth model exemplified by Ireland and South Africa. The self-funded model emphasizes level playing field and investment in education and intellectual property rights.

History has demonstrated that most countries including Vietnam are moving toward a mix of self-funded growth model and FDI growth model. Hence, we propose a few strategies that can be leveraged by global players in the Vietnamese market.

Collaboration with Local Partner

An effective approach to entering and establishing a presence in Vietnam involves partnering with a local entity that has strong connections to pharmaceutical distributors. This strategy not only helps navigate challenges related to advertising restrictions in Vietnam but also enhances brand awareness through established networks.

Appointing an Agent or Distributor

Vietnam is a challenging market for new exporters or companies lacking a robust export department or business development unit. The regulations governing marketing activities differ between Vietnam subsidiaries and representative offices. Appointing an agent or distributor will most likely alleviate these challenges.

Mergers & Acquisitions

The government is seeking to divest companies such as Binh Dinh Pharmaceuticals, Coulomb Pharmaceuticals, Trafaco, Duoc Khoa Pharmaceuticals, Ge An Pharmaceuticals, and the Vietnam Pharmaceutical Corporation.

A few instances of international companies acquiring Vietnamese pharmaceutical firms include Japan's Taisho Pharmaceutical acquiring Hausan Pharmaceutical, US-based Abott acquiring Domesco, Japan's Asuka Pharmaceutical acquiring Ha Tay Pharmaceutical, and Germany's Stada acquiring Pimefalco.

Conclusion

We expect a large gain in market share for innovative and ethical drugs as Vietnam continues to align more with common practices in the developed markets regarding quality and pricing. We also expect Vietnam's regulatory bodies to strengthen the drug distribution process which will favor ethical drug distribution and increase healthcare expenditure.

Vietnam looks a promising country for large global players, with a focused strategy to gain the maximum as Vietnam opens itself to the world.

The focus needs to be on the following:

Unmet needs of the Vietnamese population

There are multiple disease areas that are underserved such as cardiovascular, cancer, and immune system disorders which can be tapped into. Vietnamese have limited options with respect to low-cost generics and innovative and branded drugs.

Import and traditional medicine substitution

The global players need to engage in the local manufacturing of pharmaceuticals rather than relying on importation, which is also in-line with the policies of Vietnam government. Furthermore, the high cost of importation will deter the objective of faster market share growth. A sizable section of Vietnamese uses traditional medicine for indications where better alternatives in the form of modern medicine are available. Substituting this traditional medicine with modern drugs will most likely aid global players in gaining large dividends.

Leveraging expertise in complex innovative drugs and dosage form manufacturing

The global players should avoid a head on strategy against the local players in the low margin simple generic drugs. The global players are better off developing moats by leveraging their expertise such as innovative complex drugs and dosage form manufacturing and intellectual property rights to position themselves in high margin products.

Suhail Noolkar

Lead Analyst - Life Sciences & Healthcare

LinkedIn

References

- Company annual reports, SEC filing, Investor presentations, Press releases
- CRISPR Medicine Media
- Xtelligent Healthcare Media
- Innovative Genomics Institute
- Molecular biotechnology- Springer Nature Journal
- ResearchGate
- ClinicalTrials.gov
- Knowable Magazine
- THE SCIENTIST
- npj digital medicine - Nature Journal
- npj parkinson's disease - Nature Journal
- Health Services Insights - SAGE Journal
- Lilly Medicine
- Novo Nordisk Medicine
- Obesity science & practice - John Wiley & Sons Journal
- Obesity Medicine Association
- Kantar world panel
- Vietnam Briefing
- EU Trade



Disclaimer

This document makes descriptive reference to trademarks that may be owned by others. The use of such trademarks herein is not an assertion of ownership of such trademarks by SG Analytics (SGA) and is not intended to represent or get commercially benefited from it or imply the existence of an association between SGA and the lawful owners of such trademarks. Information regarding third-party products, services, and organizations was obtained from publicly available sources, and SGA cannot confirm the accuracy or reliability of such sources or information. Its inclusion does not imply an endorsement by or of any third party.

Copyright © 2024 SG Analytics Pvt. Ltd.